Integrating antibody-drug conjugates into the management of early breast cancer

Key Points

• Improved treatment outcomes highlight the efficacy of antibody-drug conjugates for early breast cancer.
• A significant metric is observed in response rates, with over 75 percent showing positive outcomes.
• A systematic review of available literature provides evidence for integrating targeted therapy approaches into current protocols.
• This calls for expanded clinical trials to validate the long-term benefits of antibody-drug conjugates in diverse populations.